Dexamethasone Treatment Options

A collection of 1456 research studies where Dexamethasone is the interventional treatment. These studies are located in the United States. Dexamethasone is used for conditions such as Multiple Myeloma, Lymphoma and Postoperative Pain.

Home

All Treatments

Dexamethasone

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

NCT02332850

Active Not Recruiting

This phase Ib trial studies the side effects and best dose of isatuximab when given together with carfilzomib with or without dexamethasone and lenalidomide in treating patients with multiple myeloma that has returned after a period of improvement (relapsed) or has not respond to previous treatment (refractory). Immunotherapy with monoclonal antibodies, such as isatuximab, may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Carfilz... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/28/2025

Locations: University of California, San Francisco, San Francisco, California +5 locations

Conditions: Multiple Myeloma

Learn More ›

Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With High-Risk Multiple Myeloma

NCT03756896

Active Not Recruiting

This phase II trial studies how well carfilzomib, pomalidomide, and dexamethasone work in treating patients with high-risk multiple myeloma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as pomalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving carfilzomib, pomalidomid... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/28/2025

Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia

Conditions: Plasma Cell Myeloma

Learn More ›

Daratumumab, Ixazomib, and Dexamethasone in AL Amyloidosis

NCT03283917

Active Not Recruiting

This phase I trial studies the side effects and best dose of daratumumab, ixazomib, and dexamethasone in treating participants with amyloid light chain amyloidosis. Monoclonal antibodies, such as daratumumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as ixazomib and dexamethasone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/28/2025

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Newly Diagnosed Primary Amyloidosis, Recurrent Primary Amyloidosis, Refractory Primary Amyloidosis

Learn More ›

CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma

NCT03798678

Active Not Recruiting

This phase I trial studies the best dose of CB-839 HCl when given together with carfilzomib and dexamethasone in treating patients with multiple myeloma that has come back or does not respond to previous treatment. CB-839 HCl and carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as dexamethasone work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividi... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/26/2025

Locations: Yale University, New Haven, Connecticut +4 locations

Conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma

Learn More ›

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

NCT03412565

Completed

The purpose of this study is to evaluate the clinical benefit of subcutaneous (SC) daratumumab administered in combination with standard multiple myeloma (MM) regimens in participants with MM as measured by overall response rate (ORR) or very good partial response (VGPR) or better rate.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/25/2025

Locations: Cancer Center of Central Connecticut - Southington, Southington, Connecticut +63 locations

Cancer Center of Central Connecticut - Southington, Southington, Connecticut

Mayo Clinic in Florida, Jacksonville, Florida

UF Health Cancer Center at Orlando Health, Orlando, Florida

Karmonos Cancer Institute, Detroit, Michigan

Providence Cancer Center, Southfield, Michigan

Billings Clinic, Billings, Montana

Nebraska Hematology and Oncology, Lincoln, Nebraska

Southeast Nebraska Cancer Center, Lincoln, Nebraska

Nebraska Cancer Specialists, Omaha, Nebraska

San Juan Oncology Associates, Farmington, New Mexico

NYU Winthrop, Mineola, New York

Mt. Sinai School of Medicine, New York, New York

Wake Forest University Baptist Medical Center (WFUBMC) - Comprehensive Cancer Center, Winston-Salem, North Carolina

Avera Medical Group - Oncology & Hematology, Sioux Falls, South Dakota

Utah Cancer Specialists, Salt Lake City, Utah

University of Virginia Cancer Center - Emily Couric Clinical Cancer Center - Women's Oncology Clinic, Charlottesville, Virginia

Liga Norte Riograndense Contra O Cancer, Natal, Not set

Associacao Hospitalar Beneficente Sao Vicente de Paulo - Hospital Sao Vicente de Paulo, Passo Fundo, Not set

Ministerio da Saude Instituto Nacional do Cancer, Rio de Janeiro, Not set

SPDM - Associacao Paulista para o Desenvolvimento da Medicina - Hospital Sao Paulo, Sao Paulo, Not set

Instituto de Assistencia Medica ao Servidor Publico Estadual IAMSPE, Sao Paulo, Not set

Clinica Sao Germano, São Paulo, Not set

Fakultni nemocnice Brno, Brno, Not set

Fakultni nemocnice Hradec Kralove, Hradec Kralove, Not set

Fakultni Nemocnice Ostrava, Ostrava, Not set

Vseobecna fakultni nemocnice v Praze - I. interni klinika - klinika hematologie, Praha 2, Not set

CHU de Nantes hotel Dieu, Nantes Cedex 1, Not set

CHU de Bordeaux - Hospital Haut-Leveque, Pessac cedex, Not set

Centre hospitalier Lyon-Sud, Pierre-Bénite, Not set

CHU Bretonneau, Tours Cedex 9, Not set

CHU Nancy Brabois, Vandoeuvre Les Nancy, Not set

Klinikum Chemnitz gGmbH, Chemnitz, Not set

Universitaetsklinikum Hamburg Eppendorf, Hamburg, Not set

Asklepios Klinik Altona, Hamburg, Not set

Universitaetsklinikum Heidelberg, Heidelberg, Not set

Universitaetsklinikum Tuebingen der Eberhard-Karls-Universitaet, Abteilung fuer Innere Medizin II,, Tübingen, Not set

Rambam Medical Center, Haifa, Not set

Carmel Medical Center, Haifa, Not set

Hadassah Medical Center, Jerusalem, Not set

Galilee Medical Center, Nahariya, Not set

Sheba Medical Center, Ramat Gan, Not set

Tel Aviv Sourasky Medical Center, Tel-Aviv, Not set

Kanazawa University Hospital, Kanazawa, Not set

Matsuyama Red Cross Hospital, Matsuyama, Not set

Nagoya City University Hospital, Nagoya, Not set

Japanese Red Cross Medical Center, Shibuya, Not set

Inst. Cat. D'Oncologia-Badalona, Badalona, Not set

Hosp Clinic de Barcelona, Barcelona, Not set

Inst. Cat. Doncologia-H Duran I Reynals, Barcelona, Not set

Hosp Univ Vall D Hebron, Barcelona, Not set

Hosp. Gral. Univ. Gregorio Maranon, Madrid, Not set

Clinica Univ. de Navarra, Madrid, Not set

Hosp. Univ. Ramon Y Cajal, Madrid, Not set

Hosp. Univ. 12 de Octubre, Madrid, Not set

Hosp. Son Llatzer, Mallorca, Not set

Clinica Univ. de Navarra, Pamplona, Not set

Hosp Clinico Univ de Salamanca, Salamanca, Not set

Hosp. Univ. Dr. Peset, Valencia, Not set

Heart of England NHS Foundation Trust, Birmingham, Not set

Royal Bournemouth Hospital, Bournemouth, Not set

Kent and Canterbury Hospital, Canterbury, Not set

Manchester Royal Infirmary, Manchester, Not set

Derriford Hospital, Plymouth, Not set

Royal Stoke University Hospital, Stoke on Trent, Not set

Conditions: Multiple Myeloma

Learn More ›

M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers

NCT03554473

Completed

BACKGROUND: * Small cell lung cancer (SCLC) is an aggressive cancer with a poor prognosis. Although highly responsive to chemotherapy initially, SCLC relapses quickly and becomes refractory to treatment within a few months. * The inability to destroy residual SCLC cells despite initial chemosensitivity suggests the existence of a highly effective deoxyribonucleic acid (DNA) damage response network. SCLC is also characterized by high DNA replication stress (retinoblastoma (RB1) inactivation, MYC and CCNE1 activation). * There is only one Food and Drug Administration (FDA) approved treatment for patients with relapsed SCLC after first-line chemotherapy: topotecan, which inhibits religation of topoisomerase I-mediated single-strand DNA breaks leading to lethal double-strand DNA breaks. Temozolomide, an oral alkylating agent, which causes DNA damage by alkylating guanine at position O6 also has activity in relapsed SCLC, particularly for brain metastases. * Preliminary evidence indicates that disruption of the immune checkpoint programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway can yield responses in a subset of SCLC patients, but response rates (approximately equal to 10%) are lower than non-small cell lung cancer (NSCLC) and other tumors with comparable tumor mutational burden indicating additional immunosuppressive mechanisms at play in the SCLC tumor microenvironment. * M7824 (MSB0011359C) is a bifunctional fusion protein consisting of an anti-programmed death ligand 1 (PDL1) antibody and the extracellular domain of transforming growth factor beta (TGF-beta) receptor type 2, a TGF-beta trap. * Safety data from the dose-escalation study in solid tumors as well as preliminary data from expansion cohorts show that M7824 has a safety profile similar to other checkpoint inhibiting compounds. * Combining immunotherapy, and chemotherapy could synergistically improve the anticancer activity of immunotherapy. Combination of chemotherapy with immunotherapy have improved outcomes in NSCLC and melanoma leading to Food and Drug Administration (FDA) approvals of such combinations. * We hypothesize that increased DNA damage induced by topotecan and temozolomide will complement the anti-tumor activity of M7824, in recurrent SCLC. OBJECTIVE: - The primary objective of the trial is to determine the efficacy (using objective response rate) of M7824 plus topotecan or temozolomide in relapsed SCLC. ELIGIBILITY: * Subjects with histological or cytological confirmation of SCLC. * Subjects must be greater than or equal to 18 years of age and have a performance status (Eastern Cooperative Oncology Group (ECOG) less than or equal to 2. * Subjects must not have received chemotherapy or undergone major surgery within 2 weeks and radiotherapy within 24 hours prior to enrollment. * Subjects must have adequate organ function and measurable disease. DESIGN: * Arm A (M7824 monotherapy): Up to 10 patients may be treated with M7824 monotherapy to obtain safety and pharmacokinetic (PK) data, and a preliminary estimate of clinical responses to M7824 in SCLC. Patients with progressive disease on Arm A may then receive M7824 plus temozolomide as per description of treatment for Arm C. * Arm B (M7824 plus topotecan) and Arm C (M7824 plus temozolomide) will be administered in 3 and 4-week cycles respectively; these arms will have a safety run-in followed by efficacy analysis. Up to 10 patients with extrapulmonary small cell cancer will be enrolled in arm C to receive the combination of M7824 and temozolomide. * Optional tumor biopsies will be obtained at pre-treatment on cycle 1 day 1 (C1D1) and C1D15 for Arm C; pre-treatment on C1D1 and cycle 2 day 1 (C2D1) for arms A and B. * Every subject of each arm of the safety run-in will be observed for at least 7 days after first dose of M7824 before the subsequent subject can be treated. Subjects who are not evaluable for dose-limiting toxicity (DLT) will be replaced and not included into evaluation. ARMS: * Arm A (3-week cycles): M7824 monotherapy 2400 mg every 3 weeks until disease progression or a criterion in Protocol is met. Patients with progressive disease on Arm A may then receive 1200 mg M7824 every 2 weeks plus temozolomide 200 mg/m\^2/day on days 1-5 every 4 weeks. * Arm B (3-week cycles): M7824 2400 mg plus topotecan 1 mg/m(2) on days 1-5 every 3 weeks until disease progression or a criterion in Protocol is met. * Arm C (4-week cycles): M7824 1200 mg every 2 weeks plus temozolomide 200 mg/m(2)/day on days 1-5 every 4 weeks until disease progression or a criterion in Protocol is met. Read Less

Gender:

ALL

Ages:

Between 18 years and 99 years

Trial Updated:

04/25/2025

Locations: National Institutes of Health Clinical Center, Bethesda, Maryland

Conditions: Carcinoma, Small Cell, Lung Cancer, Small Cell Lung Cancer

Learn More ›

A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment

NCT05455320

Recruiting

The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab SC in combination with pomalidomide and dexamethasone (DPd).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/25/2025

Locations: The University of Arizona Cancer Center, Tucson, Arizona +215 locations

The University of Arizona Cancer Center, Tucson, Arizona

University of Arkansas for Medical Sciences, Little Rock, Arkansas

Norwalk Hospital-oncology, Norwalk, Connecticut

MedStar Georgetown University Hospital, Washington, District of Columbia

George Washington University, Washington, District of Columbia

Memorial Healthcare System, Hollywood, Florida

University of Miami Health System, Miami, Florida

University Of Illinois, Chicago, Illinois

University of Kansas, Westwood, Kansas

Tulane University Hospital & Clinics, New Orleans, Louisiana

Ochsner Health System, New Orleans, Louisiana

Johns Hopkins University, Baltimore, Maryland

Massachusetts General, Boston, Massachusetts

Boston University Medical Center, Boston, Massachusetts

University of Massachusetts Medical School, Worcester, Massachusetts

University of Michigan Health System, Ann Arbor, Michigan

University Of Minnesota, Minneapolis, Minnesota

University of Mississippi Medical Center, Jackson, Mississippi

Washington University School Of Medicine, Saint Louis, Missouri

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

NYU Langone Health, New York, New York

SUNY Upstate Medical University, Syracuse, New York

University of North Carolina, Chapel Hill, North Carolina

Levine Cancer Institute, Carolinas HealthCare System, Charlotte, North Carolina

Novant Health, Charlotte, North Carolina

Novant Health, Winston-Salem, North Carolina

Wake Forest Baptist Medical Center, Winston-Salem, North Carolina

University Hospitals Cleveland Medical Center, Cleveland, Ohio

The Ohio State University Wexner Medical Center - James Cancer Hospital, Columbus, Ohio

OhioHealth, Columbus, Ohio

Thomas Jefferson University, Philadelphia, Pennsylvania

Medical University of South Carolina, Charleston, South Carolina

Baptist Cancer Center, Memphis, Tennessee

Houston Methodist Hospital, Houston, Texas

MD Anderson Cancer Center, Houston, Texas

Joe Arrington Cancer Research Treatment Center, Lubbock, Texas

Huntsman Cancer Institute, Salt Lake City, Utah

University of Virginia, Charlottesville, Virginia

Virginia Commonwealth University - Massey Cancer Center, Richmond, Virginia

Fred Hutchinson Cancer Research Center, Seattle, Washington

UZ Brussel, Brussel, Not set

UZA, Edegem, Not set

Virga Jessa Ziekenhuis, Hasselt, Not set

CHC MontLegia, Liège, Not set

Clinique Saint Pierre, Ottignies, Not set

UCL Mont Godinne, Yvoir, Not set

Fundacao Pio XII, Barretos, Not set

Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, Not set

Hospitais Integradaos da Gavea S/A - DF Star, Brasilia, Not set

Fundacao Universidade de Caxias do Sul, Caxias do Sul, Not set

Liga Paranaense de Combate ao Cancer, Curitiba, Not set

Centro de Pesquisa e Ensino em Oncologia de Santa Catarina CEPEN, Florianopolis, Not set

Liga Norte Riograndense Contra O Cancer, Natal, Not set

Irmandade Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Not set

Hospital Das Clinicas Da Faculdade De Medicina De RPUSP HCRP, Ribeirao Preto, Not set

Instituto de Educacao, Pesquisa e Gestao em Saude Instituto Americas (COI), Rio de Janeiro, Not set

Hospital Sao Rafael, Salvador, Not set

Hospital Paulistano, Sao Paulo, Not set

Instituto D Or de Pesquisa e Ensino IDOR, Sao Paulo, Not set

Fundacao Antonio Prudente A C Camargo Cancer Center, Sao Paulo, Not set

Sociedade Beneficente de Senhoras Hospital Sirio Libanes, São Paulo, Not set

Real e Benemerita Associacao Portuguesa de Beneficencia, São Paulo, Not set

Clinica Sao Germano, São Paulo, Not set

Peking Union Medical College Hospital, Beijing, Not set

Beijing Chaoyang Hospital, Beijing, Not set

Peking University First Hospital, Beijing, Not set

The First Hospital of Jilin University, Changchun, Not set

The second Xiangya Hospital of Central South University, ChangSha, Not set

Sichuan Academy of Medical Science Sichuan Provincial People's Hospital, Chengdu, Not set

Fujian Medical University Union Hospital, Fuzhou, Not set

Sun Yat Sen University Cancer Center, Guang Zhou Shi, Not set

Guangdong Provincial People's Hospital, Guangzhou, Not set

The First Affiliated Hospital Zhejiang University College of Medicine, Hangzhou, Not set

Nanjing Drum Tower Hospital, Nanjing, Not set

Tongji Hospital of Tongji University, Shanghai, Not set

Shanghai Fourth People s Hospital, Shanghai, Not set

Peking University Shenzhen Hospital, Shenzhen, Not set

First Affiliated Hospital SooChow University, Su Zhou, Not set

Tianjin cancer hospital, Tianjin, Not set

Institute of Hematology & Blood Disease Hospital Chinese Academy of Medical Science, Tianjin, Not set

Tongji Hospital, Tongji Medical College of HUST, Wuhan, Not set

Henan Cancer Hospital, Zhengzhou, Not set

Fakultni nemocnice Brno, Brno, Not set

Fakultni nemocnice Hradec Kralove, Hradec Kralove, Not set

Fakultni nemocnice Olomouc, Olomouc, Not set

Fakultni Nemocnice Ostrava, Ostrava - Poruba, Not set

Fakultni nemocnice Kralovske Vinohrady, Praha 10, Not set

Vseobecna fakultni nemocnice v Praze - I. interni klinika - klinika hematologie, Praha 2, Not set

APHP - Hopital Henri Mondor, Creteil, Not set

CHU Dijon, Dijon, Not set

Centre Leon Berard, Lyon, Not set

CHU de Montpellier - Hopital Saint-Eloi, Montpellier Cedex 5, Not set

CHU de Nantes hotel Dieu, Nantes, Not set

CHU HOPITAL DE L'ARCHET - Hematology, Nice N/a, Not set

CHU Hopital Saint Antoine, Paris Cedex 12, Not set

CHRU - Hôpital du Haut Lévêque - Centre François Magendie, Pessac, Not set

Institut Universitaire du cancer de Toulouse-Oncopole, TOULOUSE Cedex 9, Not set

Charite Campus Benjamin Franklin, Berlin, Not set

Asklepios Klinik Altona, Hamburg, Not set

Universitaetsklinikum Heidelberg, Heidelberg, Not set

Universitaetsklinikum Koelnt, Koeln, Not set

Universitaetsklinikum Leipzig, Leipzig, Not set

Universitätsmedizin der Johannes Gutenberg Universität, Mainz, Not set

Universitaetsklinikum Wuerzburg, Wuerzburg, Not set

Alexandra General Hospital of Athens, Athens Attica, Not set

G Papanikolaou Hospital of Thessaloniki, Thessalonikis, Not set

Anticancer Hospital of Thessaloniki Theageneio, Thessaloniki, Not set

Ha'Emek Medical Center, Afula, Not set

Shamir Medical Center Assaf Harofeh, Be Er Ya Akov, Not set

Hillel Yaffe Medical Center, Hadera, Not set

Bnai Zion Medical Center, Haifa, Not set

Rambam Medical Center, Haifa, Not set

Carmel Medical Center, Haifa, Not set

Shaare Zedek Medical Center, Jerusalem, Not set

Galilee Medical Center, Nahariya, Not set

Beilinson medical center, Petah Tikva, Not set

Sheba Medical Center, Ramat Gan, Not set

Ziv Medical Center, Safed, Not set

Sourasky (Ichilov) Medical Center, Tel Aviv, Not set

A.O. Universitaria Ospedali Riuniti di Ancona, Ancona, Not set

Policlinico di Bari, Bari, Not set

Azienda Ospedaliera Policlinico S. Orsola-Malpighi, Bologna, Not set

Azienda Ospedaliera Spedali Civili di Brescia, Brescia, Not set

PO G.Rodolico, AOU Policlinico-Vittorio Emanuele Catania, Catania, Not set

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Not set

ASST Grande Ospedale Metropolitano Niguarda, Milano, Not set

Azienda Ospedaliera Universitaria di Padova, Padova, Not set

Ospedale Villa Sofia-Cervello, Palermo, Not set

Fondazione IRCCS Policlinico San Matteo, Pavia, Not set

Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, Not set

Presidio Ospedaliero Santo Spirito in Sassia, Roma, Not set

IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Not set

A.O.U. Città della Salute e della Scienza, Torino, Not set

Institute of Science Tokyo Hospital, Bunkyo ku, Not set

Chiba Cancer Center, Chiba, Not set

Fukuoka University Hospital, Fukuoka, Not set

Ogaki Municipal Hospital, Gifu, Not set

Gunma University Hospital, Gunma, Not set

Kansai Medical University Hospital, Hirakata, Not set

Japanese Red Cross Society Himeji Hospital, Hyogo, Not set

Hyogo Medical University Hospital, Hyôgo, Not set

Shonan Kamakura General Hospital, Kamakura-shi, Not set

National Cancer Center Hospital East, Kashiwa, Not set

Dokkyo Medical University Saitama Medical Center, Koshigaya, Not set

Kumamoto University Hospital, Kumamoto, Not set

Kyoto Kuramaguchi Medical Center, Kyoto, Not set

National Hospital Organization Matsumoto Medical Center, Matsumoto, Not set

Niigata Cancer Center Hospital, Niigata, Not set

National Hospital Organization Hiroshima-Nishi Medical Center, Otake, Not set

Hokkaido University Hospital, Sapporo-shi, Not set

Tohoku University Hospital, Sendai, Not set

Iwate Medical University Hospital, Shiwa-gun, Not set

The University of Osaka Hospital, Suita City, Not set

The Cancer Institute Hospital of JFCR, Tokyo, Not set

Dong-A University Hospital, Busan, Not set

National Cancer Center, Gyeonggi-do, Not set

Gachon University Gil Medical Center, Incheon, Not set

Chonnam National University Hwasun Hospital, Jeollanam-do, Not set

Jeonbuk National University Hospital, Jeonju-si, Not set

Seoul National University Hospital, Seoul, Not set

Severance Hospital Yonsei University Health System, Seoul, Not set

Asan Medical Center, Seoul, Not set

Samsung Medical Center, Seoul, Not set

The Catholic University of Korea Seoul St Marys Hospital, Seoul, Not set

Albert Schweitzer ziekenhuis-lokatie Dordwijk, Dordrecht, Not set

Maxima Medisch Centrum, Eindhoven, Not set

Erasmus MC, Rotterdam, Not set

Szpital Specjalistyczny w Brzozowie Podkarpacki Osrodek Onkologiczny im Ks B Markiewicza, Brzozow, Not set

Uniwersyteckie Centrum Kliniczne, Gdansk, Not set

Pratia Onkologia Katowice, Katowice, Not set

Swietokrzyskie Centrum Onkologii SPZOZ w Kielcach, Kielce, Not set

Szpital Uniwersytecki w Krakowie, Krakow, Not set

Centrum Onkologii Ziemi Lubelskiej im sw Jana z Dukli, Lublin, Not set

Szpital Kliniczny MSWiA z Warminsko Mazurskim Centrum Onkologii w Olsztynie Oddzial Hematologii, Olsztyn, Not set

Uniwersytecki Szpital Kliniczny Nr 1 PUM im prof Tadeusza Sokolowskiego w Szczecinie, Szczecin, Not set

Wojewodzki Szpital Zespolony im L Rydygiera w Toruniu, Torun, Not set

Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy, Warszawa, Not set

Uniwersytecki Szpital Kliniczny im Jana Mikulicza Radeckiego we Wroclawiu, Wroclaw, Not set

Hosp. Univ. Germans Trias I Pujol, Badalona, Not set

Hosp. de La Santa Creu I Sant Pau, Barcelona, Not set

Hosp Univ Vall D Hebron, Barcelona, Not set

Hosp Clinic de Barcelona, Barcelona, Not set

Hosp. Univ. Virgen de La Arrixaca, El Palmar, Not set

Hosp. de Jerez de La Frontera, Jerez de la Frontera, Not set

Hosp. de Leon, Leon, Not set

Hosp. Univ. de La Princesa, Madrid, Not set

Hosp. Univ. Ramon Y Cajal, Madrid, Not set

Hosp. Univ. 12 de Octubre, Madrid, Not set

Hosp Univ Hm Sanchinarro, Madrid, Not set

Hosp Virgen de La Victoria, Malaga, Not set

Clinica Univ. de Navarra, Pamplona, Not set

Hosp Clinico Univ de Salamanca, Salamanca, Not set

Hosp. Univ. de Canarias, San Cristóbal de La Laguna, Not set

Hosp. Univ. Dr. Peset, Valencia, Not set

Kaohsiung Medical University Chung Ho Memorial Hospital, Kaohsiung, Not set

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Not set

China Medical University Hospital, Taichung City, Not set

National Cheng Kung University Hospital, Tainan, Not set

National Taiwan University Hospital, Taipei, Not set

Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Hematology Unit, Ankara, Not set

Ankara University Medical Faculty, Ankara, Not set

Liv Hospital Ankara, Ankara, Not set

Antalya Training And Research Hospital, Antalya, Not set

Medipol Mega University Hospital, Istabul, Not set

Istanbul University Istanbul Medical Faculty, Istanbul, Not set

Istanbul University Cerrahpasa Medical Faculty, Istanbul, Not set

Dokuz Eylul University Medical Faculty, Izmir, Not set

Ondokuz Mayis University, Samsun, Not set

Blackpool Victoria Hospital, Blackpool, Not set

Ninewells Hospital & Medical School, Dundee, Not set

Hammersmith Hospital, London, Not set

Newcastle Freeman Hospital, Newcastle Upon Tyne, Not set

Nottingham City Hospital, Nottingham, Not set

University Hospitals Plymouth NHS Trust, Plymouth, Not set

Royal Marsden Hospital, Sutton, Not set

New Cross Hospital, Wolverhampton, Not set

Conditions: Relapsed or Refractory Multiple Myeloma

Learn More ›

Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

NCT02136134

Completed

The purpose of this study is to assess the effects of administration of daratumumab when combined with VELCADE (bortezomib) and dexamethasone compared with bortezomib and dexamethasone alone, for participants with relapsed or refractory multiple myeloma.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/25/2025

Locations: Not set, Birmingham, Alabama +106 locations

Not set, Birmingham, Alabama

Not set, Los Angeles, California

Not set, Stamford, Connecticut

Not set, Jacksonville, Florida

Not set, Atlanta, Georgia

Not set, Niles, Illinois

Not set, Topeka, Kansas

Not set, Westwood, Kansas

Not set, Marrero, Louisiana

Not set, Boston, Massachusetts

Not set, Lansing, Michigan

Not set, New York, New York

Not set, Chapel Hill, North Carolina

Not set, Portland, Oregon

Not set, Philadelphia, Pennsylvania

Not set, Providence, Rhode Island

Not set, Seattle, Washington

Not set, Adelaide, Not set

Not set, Concord, Not set

Not set, Fitzroy, Not set

Not set, Hobart, Not set

Not set, Melbourne, Not set

Not set, Nedlands, Not set

Not set, Woodville South, Not set

Not set, Barretos, Not set

Not set, Porto Alegre, Not set

Not set, Salvador, Not set

Not set, Sao Paulo, Not set

Not set, São Paulo, Not set

Not set, Brno, Not set

Not set, Hradec Kralove, Not set

Not set, Ostrava-Poruba, Not set

Not set, Praha 10, Not set

Not set, Praha 2, Not set

Not set, Bamberg, Not set

Not set, Berlin, Not set

Not set, Duesseldorf, Not set

Not set, Freiburg, Not set

Not set, Göttingen, Not set

Not set, Hamburg, Not set

Not set, Mainz, Not set

Not set, München, Not set

Not set, Stuttgart, Not set

Not set, Tübingen, Not set

Not set, Ulm, Not set

Not set, Würzburg, Not set

Not set, Budapest, Not set

Not set, Debrecen, Not set

Not set, Győr, Not set

Not set, Pecs, Not set

Not set, Veszprém, Not set

Not set, Busan, Not set

Not set, Hwasun, Not set

Not set, Seoul, Not set

Not set, Suwon, Not set

Not set, Ulsan, Not set

Not set, Huixquilucan, Not set

Not set, Monterrey, Not set

Not set, Alkmaar, Not set

Not set, Amersfoort, Not set

Not set, Den Haag, Not set

Not set, Dordrecht, Not set

Not set, Groningen, Not set

Not set, Leiden, Not set

Not set, Maastricht, Not set

Not set, Nijmegen, Not set

Not set, Chorzow, Not set

Not set, Katowice, Not set

Not set, Krakow, Not set

Not set, Poznan, Not set

Not set, Warszawa, Not set

Not set, Krasnodar, Not set

Not set, Moscow, Not set

Not set, Nizhny Novgorod, Not set

Not set, Penza, Not set

Not set, Pyatigorsk, Not set

Not set, Ryazan, Not set

Not set, Samara, Not set

Not set, Sochi, Not set

Not set, Syktyvkar, Not set

Not set, Madrid, Not set

Not set, Salamanca, Not set

Not set, San Sebastian de los Reyes, Not set

Not set, Toledo, Not set

Not set, Valencia, Not set

Not set, Linkoping, Not set

Not set, Lulea, Not set

Not set, Lund, Not set

Not set, Orebro, Not set

Not set, Sundsvall, Not set

Not set, Umea, Not set

Not set, Uppsala, Not set

Not set, Västerås, Not set

Not set, Ankara, Not set

Not set, Istanbul, Not set

Not set, Izmir, Not set

Not set, Kayseri, Not set

Not set, Kocaeli, Not set

Not set, Malatya, Not set

Not set, Cherkasy, Not set

Not set, Dnepropetrovsk, Not set

Not set, Ivano-Frankivsk, Not set

Not set, Kiev, Not set

Not set, Lviv, Not set

Not set, Poltava, Not set

Not set, Vinnitsa, Not set

Not set, Zaporizhzhya, Not set

Conditions: Multiple Myeloma

Learn More ›

Daratumumab in Combination With Lenalidomide and Dexamethasone in Relapsed and Relapsed-refractory Multiple Myeloma

NCT01615029

Completed

The purpose of this study is to establish the safety profile of daratumumab when given in combination with Lenalidomide and dexamethasone in participants with relapsed or relapsed and refractory Multiple Myeloma (MM).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/24/2025

Locations: Not set, Boston, Massachusetts +7 locations

Conditions: Multiple Myeloma

Learn More ›

Physical Activity and Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Advanced Cancer

NCT02491632

Active Not Recruiting

This randomized phase II trial studies how well physical activity and dexamethasone work in reducing cancer-related fatigue in patients with cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment (advanced). Dexamethasone is approved for the treatment of tiredness, pain, and nausea. Physical activity may help improve cancer-related fatigue by improvement in symptoms, distress, and overall well-being. It is not yet known whether high dose or lo... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/24/2025

Locations: M D Anderson Cancer Center, Houston, Texas

Conditions: Advanced Malignant Neoplasm, Fatigue, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm, Refractory Malignant Neoplasm

Learn More ›

A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

NCT01998971

Completed

The purpose of this study is to evaluate the safety, tolerability, and dose regimen of daratumumab when administered in combination with various treatment regimens for the treatment of multiple myeloma.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/24/2025

Locations: Not set, Duarte, California +21 locations

Conditions: Multiple Myeloma

Learn More ›

RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer

NCT00253318

Terminated

Primary: * To assess the safety and tolerability and to find the maximum tolerated dose of the combination administration of RAD001 plus docetaxel when given to patients with metastatic breast cancer who are being considered for standard docetaxel treatment (phase I). * To characterize the pharmacokinetics of RAD001 and docetaxel when co-administered (phase I). Secondary: * To determine the phosphorylation status of the components of the mTOR signaling pathway and the expression of modifiers... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

04/24/2025

Locations: UT MD Anderson Cancer Center, Houston, Texas

Conditions: Breast Cancer

Learn More ›

Browse by State

Dexamethasone treatment options in Alabama

Dexamethasone treatment options in Alaska

Dexamethasone treatment options in Arizona

Dexamethasone treatment options in Arkansas

Dexamethasone treatment options in California

Dexamethasone treatment options in Colorado

Dexamethasone treatment options in Connecticut

Dexamethasone treatment options in Delaware

Dexamethasone treatment options in District of Columbia

Dexamethasone treatment options in Florida

Dexamethasone treatment options in Georgia

Dexamethasone treatment options in Hawaii

Dexamethasone treatment options in Idaho

Dexamethasone treatment options in Illinois

Dexamethasone treatment options in Indiana

Dexamethasone treatment options in Iowa

Dexamethasone treatment options in Kansas

Dexamethasone treatment options in Kentucky

Dexamethasone treatment options in Louisiana

Dexamethasone treatment options in Maine

Dexamethasone treatment options in Montana

Dexamethasone treatment options in Nebraska

Dexamethasone treatment options in Nevada

Dexamethasone treatment options in New Hampshire

Dexamethasone treatment options in New Jersey

Dexamethasone treatment options in New Mexico

Dexamethasone treatment options in New York

Dexamethasone treatment options in North Carolina

Dexamethasone treatment options in North Dakota

Dexamethasone treatment options in Ohio

Dexamethasone treatment options in Oklahoma

Dexamethasone treatment options in Oregon

Dexamethasone treatment options in Maryland

Dexamethasone treatment options in Massachusetts

Dexamethasone treatment options in Michigan

Dexamethasone treatment options in Minnesota

Dexamethasone treatment options in Mississippi

Dexamethasone treatment options in Missouri

Dexamethasone treatment options in Pennsylvania

Dexamethasone treatment options in Rhode Island

Dexamethasone treatment options in South Carolina

Dexamethasone treatment options in South Dakota

Dexamethasone treatment options in Tennessee

Dexamethasone treatment options in Texas

Dexamethasone treatment options in Utah

Dexamethasone treatment options in Vermont

Dexamethasone treatment options in Virginia

Dexamethasone treatment options in Washington

Dexamethasone treatment options in West Virginia

Dexamethasone treatment options in Wisconsin

Dexamethasone treatment options in Wyoming